🇺🇸 FDA

Drug profile · INN

roflumilast

DAXAS

approved R03DX07
US status
approved
Patents linked
8
News articles
0

Quick answer

roflumilast (DAXAS) is an FDA-listed pharmaceutical active ingredient. Associated with Arcutis Biotherapeutics. Route of administration: topical. Current US regulatory status: approved.

Key facts

INN roflumilast
Brand DAXAS
Route TOPICAL
Formulation FOAM
ATC code R03DX07
Originator Arcutis Biotherapeutics

Related patents

Search patents →

  1. US 12336983

    Inhibition of crystal growth of roflumilast

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12329751

    Topical roflumilast formulation having antifungal properties

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12310956

    Topical roflumilast formulation having improved delivery and plasma half-life

    Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12257242

    Inhibition of crystal growth of roflumilast

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12220409

    Roflumilast formulations with an improved pharmacokinetic profile

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12144802

    Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12042558

    Method and formulation for improving roflumilast skin penetration lag time

    Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12016848

    Roflumilast formulations with an improved pharmacokinetic profile

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is roflumilast?

roflumilast (DAXAS) is an FDA-listed pharmaceutical active ingredient. Associated with Arcutis Biotherapeutics. Route of administration: topical. Current US regulatory status: approved.

What is the brand name for roflumilast?

DAXAS is a marketed brand name for roflumilast. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of roflumilast?

roflumilast has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.